ARA-290 (also known as cibinetide) is an 11-amino-acid synthetic peptide derived from erythropoietin (EPO). It is specifically engineered to target the innate repair receptor (IRR). While natural EPO stimulates red blood cell production, ARA-290 provides the tissue-protective and anti-inflammatory properties of EPO without affecting red blood cells, thereby avoiding the risk of blood clots or high blood pressure
The primary health benefits of ARA-290 documented in clinical trials and preclinical studies include:
Nerve pain reduction: Studies show that ARA-290 significantly lowers pain scores and improves symptoms in individuals suffering from small fiber neuropathy (SFN) and chronic neuropathic pain.
Allodynia management: It effectively reduces allodynia, a condition where normally non-painful stimuli (like a light touch or cold) cause severe pain.
Axon regrowth: Unlike traditional painkillers tha only mask symptoms, ARA-290 addresses underlying nerve damage by stimulating the regrowth of small nerve fibers.
Increased fiber density: Clinical observations show a measurable increase in corneal nerve fiber density (CNFD) in patients with nerve damage caused by diabetes or sarcoidosis.
Microglia suppression: ARA-290 works within the central nervous system to suppress the activation of spinal cord microglia, which are key drivers of chronic inflammation and sustained pain states.
Cytokine regulation: It dampens systemic inflammation by downregulating pro-inflammatory pathways (such as NF-kB) and reducing tissue-damaging inflammatory markers.
HbA1c improvement: Phase II clinical trials demonstrate that daily administration of ARA-290 over 28 days leads to improved hemoglobin A1c levels, indicating better long-term blood sugar regulation.Enhanced lipid profiles: It helps optimize cholesterol and lipid panels in metabolic-compromised subjects.
Enhanced lipid profiles: It helps optimize cholesterol and lipid panels in metabolic-compromised subjects.
Ischemia and toxicity shield: Preclinical research indicates that the peptide protects vital organs by preventing cellular apoptosis (programmed cell death) during injuries, environmental toxicity, or low-oxygen events.
Organ support: Studies have explored its potential in safeguarding the heart, kidneys, and eyes from chronic inflammatory degradation.
Exercise tolerance: In clinical trials evaluating patients with chronic conditions like sarcoidosis-associated neuropathy, ARA-290 therapy resulted in statistically significant increases in exercise capacity, measured by the standard 6-minute walk test.